In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic fragment Nangibotide | Natural fragment Thymosin alpha-1 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic fragment | Natural fragment | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 140 | 1,450 (plus 251 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 18 (17 in people) | 54 (45 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 1 · 1 active | 56 · 13 active9 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Nangibotide | Thymosin alpha-1 |
|---|---|---|
| Immune responseRespiratory | 8233 | 562 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| MortalityWhole body | 862 | 947816 |
|---|
| Inflammation markersRespiratory | 22211 | 110404129 |
|---|
| Adverse eventsWhole body | 99 | 5647441 |
|---|
| Intensive care and hospital outcomesWhole body | 761 | 3838 |
|---|
| Liver fat and liver functionLiver | 33 | 41392 |
|---|
| Receptor activity and mechanismRespiratory | 231157 | 1025934 |
|---|
| PharmacokineticsPharmacology | 77 | 3411212 |
|---|
| Respiratory functionRespiratory | 11 | 1717 |
|---|
| Overall treatment effectWhole body | 55 | 66 |
|---|
| Heart functionCardiovascular | 1515 | 11 |
|---|
| Lung injury and fibrosisRespiratory | 66 | 44 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Thymosin alpha-1 is the same as Prothymosin alpha (human) residues 2 to 29, with 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Inotrem355 participants13 Nov 2019 to est. 9 May 2023
Shock, Septic
Top 3 of 56 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Shanghai Jiao Tong University School of Medicine2,944 participants21 Jan 2020 to est. Jun 2020
2019 Novel Coronavirus Infection
Fudan University2,500 participants1 Apr 2021 to est. 31 Mar 2027
Stage II Colorectal Cancer · Stage III Colorectal Cancer
Sun Yat-sen University1,106 participants6 Sept 2016 to 23 Mar 2021
Sepsis
9 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Nangibotide | Thymosin alpha-1 |
|---|---|---|
| MortalityInfectionCompared as: value in the arm that got the peptide, in % | 16% Mortality at day 28 Placebo: 28% Dose studied: 1.0 mg/kg/hn = 2192023 | 26% 28-day mortality · thymosin alpha 1 Control: 35% n = 3612013 |
16%
Mortality at day 28
Placebo: 28%
Dose studied: 1.0 mg/kg/hn = 2192023
26%
28-day mortality · thymosin alpha 1
Control: 35%
n = 3612013
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Nangibotide | Thymosin alpha-1 |
|---|---|---|
| Overall treatment effectWhole bodyCompared as: share of people in the arm that got the peptide, in % | 64.7% Patients with improved clinical status at day 28 Placebo: 52% Dose studied: 1.0 mg/kg/hn = 2192023 |
No comparable result 3 randomized-trial results measure it in another way or another unit. |
64.7%
Patients with improved clinical status at day 28
Placebo: 52%
Dose studied: 1.0 mg/kg/hn = 2192023
No comparable result
3 randomized-trial results measure it in another way or another unit.